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Abstract 
Introduction 
Castration-resistant prostate cancer (CRPC) is a type of prostate cancer that 
keeps growing even when the testosterone level is reduced to very low levels. 
Darolutamide is a nonsteroidal androgen receptor (AR) antagonist with a mo-
lecular structure that differs from other AR antagonists. To date, darolutam-
ide is neither approved by the European Medicines Agency (EMA) nor by the 
U.S. Food and Drug Administration (FDA) for any indication. 
Methodology 
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD Database, Embase, Ovid Medline, PubMed, Internet sites and 
contacting the manufacturer, resulting in 95 references overall. A quality as-
sessment was conducted to assess the risk of bias at the study level based on 
the EUnetHTA internal validity for randomised controlled trials. To evaluate 
the magnitude of “clinically meaningful benefit” that can be expected from a 
new anti-cancer treatment, the Magnitude of Clinical Benefit Scale developed 
by the European Society for Medical Oncology (ESMO-MCBS) was used. 
Results from the ARAMIS trial 
The ARAMIS trial aimed to investigate the efficacy and safety of darolutam-
ide compared to placebo in men with nonmetastatic CRPC. The trial is cur-
rently ongoing; thus, presented data are primary- and interim results. The 
primary analysis of median metastasis-free survival (MFS) showed a gain of 
22 months in patients who received darolutamide compared to patients who 
received placebo (HR for metastasis or death in the darolutamide group was 
0.41). This beneficial treatment effect of darolutamide was observed across all 
pre-specified subgroups. An interim analysis of OS showed a lower risk of 
death with darolutamide as compared to placebo (HR for death was 0.71); 
however, median OS data have not been reached in either group. Progression-
free survival (PFS, an exploratory endpoint) was statistically significantly 
longer (36.8 months) in patients of the darolutamide group than in patients 
of the placebo group (14.8 months). In patients receiving darolutamide, the 
time to pain progression and the time to prostate-specific antigen (PSA) pro-
gression were prolonged by 14.9 months and 25.9 months, respectively. 
Health-related quality of life (HRQoL) and disease specific quality of life 
(QoL) were evaluated by the use of five different questionnaires. Overall, pa-
tient-reported QoL was similar between the two treatment groups. 
Conclusion 
The ARAMIS trial showed that darolutamide provides a prolongation of MFS 
in patients with nonmetastatic CRPC and was associated with better out-
comes regarding disease progression as compared to placebo. However, the 
presented data are the primary and interim analysis; final results of all end-
points are lacking. Hence, the actual clinical benefit of darolutamide is not 
yet proven. In this regard, more data concerning efficacy, safety and long-term 
results is required, as well as a direct comparison with other AR antagonists 
to determine the optimal treatment for affected patients. Darolutamide is cur-
rently not approved, but may provide an additional treatment option for pa-
tients with nonmetastatic CRPC. 
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of Phar-
maceuticals was used for structuring this report [1]. The Model organises 
HTA information according to pre-defined generic research questions. Based 
on these generic questions, the following research questions were answered in 
the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is darolutamide? 
A0022 Who manufactures darolutamide? 
A0007 What is the target population in this assessment? 
A0020 For which indications has darolutamide received marketing authorisation? 
Health problem and current use 
A0002 What is prostate cancer? 
A0004 What is the natural course of prostate cancer? 
A0006 What are the consequences of prostate cancer for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of prostate cancer? 
A0003 What are the known risk factors for prostate cancer? 
A0024 
How is prostate cancer currently diagnosed according to published guidelines and in 
practice? 
A0025 
How is prostate cancer currently managed according to published guidelines and in 
practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of darolutamide on mortality? 
D0006 How does darolutamide affect progression (or recurrence) of prostate cancer? 
D0005 
How does darolutamide affect symptoms and findings (severity, frequency) of prostate 
cancer? 
D0011 What is the effect of darolutamide on patients ̕ body functions? 
D0012 What is the effect of darolutamide on generic health-related quality of life? 
D0013 What is the effect of darolutamide on disease-specific quality of life? 
Safety 
C0008 How safe is darolutamide in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying darolutamide? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of darolutamide? 
A0021 What is the reimbursement status of darolutamide? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Darolutamide/-/L02BB06 
 
B0001: What is darolutamide? 
Darolutamide (developmental code names: ODM-201, BAY-1841788) is a 
nonsteroidal androgen receptor (AR) antagonist with a molecular structure 
that differs from other AR antagonists. Darolutamide and its active metabo-
lite inhibit testosterone-induced translocation of AR to the nucleus. This 
mechanism prevents the binding to and the transcription of genes that regu-
late the proliferation of prostate cancer cells, resulting in an inhibition of 
growth in AR-expressing prostate cancer cells [2, 3].  
Patients of the ARAMIS trial received darolutamide at a dose of 600 mg given 
as two 300 mg tablets twice daily (total daily dose of 1,200 mg) with food, or 
matching placebo tablets which were indistinguishable from darolutamide 
tablets. Throughout the trial, patients continued to receive a luteinising hor-
mone (LH)-releasing hormone agonist or antagonist for androgen-deprivation 
therapy (ADT). 
According to the ARAMIS trial protocol [4], the interaction of darolutamide 
(at therapeutic dose level, based on nonclinical data) with other drugs is un-
likely. Plasma concentration of drugs that are primary metabolised or acti-
vated by P450 CYP2C9 or drugs that are sensitive substrates to P-glycoprotein 
(P-gp) inhibition might be affected by darolutamide. Medicinal products that 
are sensitive substrates for P-gp, such as digoxin, should be used with caution 
when co-administered with darolutamide. If patients are treated with both 
darolutamide and drugs metabolised by CYP2C9 with a narrow therapeutic 
index, they should be monitored for possible increased therapeutic effects. In 
patients who are treated with warfarin, International Normalized Ratio (INR) 
monitoring should be conducted.  
Although no stand-alone developmental and reproductive toxicity studies 
have been conducted with darolutamide, decreased fertility in males and de-
velopmental toxicity would be expected on the basis of the known pharmaco-
logic effects of antiandrogens. It also has to be considered that the ARAMIS 
trial patients received gonadotropin-releasing hormone (GnRH) agonist or 
antagonist treatment throughout the trial, which affects fertility [4]. 
 
A0022: Who manufactures darolutamide? 
Bayer HealthCare and Orion Pharma. 
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3 Indication 
A0007: What is the target population in this assessment? 
Darolutamide is indicated in patients with nonmetastatic castration-re-
sistant prostate cancer (CRPC) and a PSA doubling time (PSADT) of ten 
months or less. 
 
 
4 Current regulatory status 
A0020: For which indications has darolutamide received marketing authori-
sation? 
To date, darolutamide is neither approved by the European Medicines Agency 
(EMA) nor by the U.S. Food and Drug Administration (FDA) for any indica-
tion. 
Based on data from the ARAMIS trial, the manufacturer submitted a market-
ing authorisation application to the EMA for darolutamide for the treatment 
of patients with nonmetastatic CRPC in March 2019 [5]. The submission of a 
New Drug Application to the FDA for darolutamide was initiated in Decem-
ber 2018; the rolling submission
1
 was completed in February 2019 [6, 7]. 
 
 
5 Burden of disease 
A0002: What is prostate cancer? 
Prostate cancer is the most frequent cancer in men in Austria [8] and is among 
the most common cancers worldwide [9]. The majority of prostate cancers are 
adenocarcinomas, developing from the gland cells. Other types of prostate can-
cers, including sarcomas, small cell carcinomas, neuroendocrine tumours (other 
than small cell carcinomas) and transitional cell carcinomas, are rare.  
CRPC is a type of prostate cancer that keeps growing even when the testosterone 
level is reduced to very low levels [10]. CRPC is defined as a castrate serum 
testosterone <50 ng/dl or 1.7 nmol/l and has either one of the following pro-
gression characteristics: 
 Biochemical progression: three consecutive rises in PSA one week 
apart (resulting in two 50% increases over the nadir) and PSA >2 
ng/ml, or 
                                                             
1
 In the course of a rolling submission, which is a dose in waves, completed sections - 
as opposed to the entire application - are submitted for review by the sponsors (e.g., 
the nonclinical portion in the first wave, followed by a chemistry, manufacturing and 
control wave, and a final wave containing clinical data). 
 
men with nonmetastatic 
PSA and PSADT ≤10 
months  
NOT approved by the 
EMA and the FDA 
EMA: marketing 
authorisation 
submitted,  
FDA: rolling submission 
completed 
most common cancer in 
men in Austria 
CRCP grows despite low 
testosterone levels 
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 Radiologic progression: the appearance of two or more new lesions on 
bone scan or a soft tissue lesion using the Response Evaluation Criteria 
in Solid Tumours (RECIST) [11]. 
Patients with nonmetastatic CRPC show rising PSA and castrate testosterone 
levels, with no radiological findings of metastatic disease on computed tomog-
raphy (CT) and bone scan [12]. 
 
A0004: What is the natural course of prostate cancer? 
According to data from the US population, 77% of prostate cancers are diag-
nosed at a local stage (confined to primary site), 12% are diagnosed at a re-
gional stage (spread to regional lymph nodes) and 6% of prostate cancer cases 
are diagnosed at a distant stage, when the cancer has already metastasized 
(4% of prostate cancer cases remain unstaged) [13]. 
In Austria, the relative survival rate following diagnosis in patients with pros-
tate cancer (2009–2013) is 95.6% at one year, 93.1% at three years and 91.5% 
at five years. In 2016, the age-standardised mortality rate for the European 
Standard Population (2013) was 38.7 per 100,000 men per year. In 2016, 1,225 
men died from prostate cancer in Austria. At the end of the year 2016, 63,415 
men diagnosed with prostate cancer were alive; more than 40% of the affected 
patients (25,572 men) were diagnosed at least ten years ago [8].  
 
A0006: What are the consequences of prostate cancer for the society? 
A0023: How many people belong to the target population? 
In Austria, 5,245 men per year (2016) are newly diagnosed with prostate can-
cer. The age-standardised incidence rate for the European Standard Popula-
tion (2013) is 138.3 per 100,000 men per year (2016) [8].  
Since there is a lack of European data regarding age at diagnosis and detailed 
incidence as well as prevalence data, information from the US is reported in 
the following. In the US, the incidence and prevalence of nonmetastatic 
CRPC was estimated at 50,000–60,000 men per year and 100,000 men, respec-
tively, with a 34% annual progression to metastatic CRPC; overall mortality 
was 16% [14]. According to data from the US, prostate cancer is most fre-
quently diagnosed among men between the ages of 65 and 74 years; the me-
dian age at diagnosis is 66 years [13]. 
 
A0005: What are the symptoms and the burden of prostate cancer? 
Most cases of prostate cancer are diagnosed at the local stage when patients 
are asymptomatic. Patients rarely present with nonspecific urinary symptoms 
including haematuria or haematospermia that are usually associated with 
non-malignant conditions [9]. 
Patients with metastatic disease at the time of diagnosis may present with 
bone pain; other symptoms are weight loss, weakness or pain caused by spinal 
cord compression or due to pathologic fractures, fatigue due to anaemia, renal 
or urinary symptoms (haematuria, inability to void, incontinence) as well as 
symptoms that are associated with chronic renal failure. A clinical sign that 
can be associated with prostate cancer is an elevation of PSA on laboratory 
testing. However, PSA is not specific for malignancy, since an elevation may 
no radiological findings 
in men with 
nonmetastatic CRPC 
77% of prostate cancers 
are diagnosed at the 
local stage 
Austria: 5-year relative 
survival rate of 91.5%  
Austria: incidence rate 
of 138.3/100,000 
men/year 
 
median age at diagnosis: 
66 years 
mostly diagnosed at 
asymptomatic, local 
stage 
symptoms of metastatic 
disease 
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also be caused by a number of benign conditions. Although PSA is not specific 
for prostate cancer, the measurement of the PSA level is the most commonly 
used and most valuable test to detect prostate cancer at an early stage. Further 
clinical signs that may indicate the presence of prostate cancer are abnormal 
findings on the digital rectal examination (DRE). A DRE may enable the de-
tection of prostate nodules, indurations or asymmetries potentially associated 
with prostate cancer. However, only tumours that are localised in the poste-
rior and lateral aspects of the prostate gland can be detected by a DRE; tu-
mours in other parts of the gland are not reachable or not palpable, such as 
small, stage T1 cancers [9]. 
 
A0003: What are the known risk factors for prostate cancer? 
The risk for the development of clinically significant prostate cancer is related 
to the following factors [9, 15-18]:  
 Age: Increasing age is the most important risk factor for the develop-
ment of prostate cancer. The disease is rare in men younger than 40 
years, but its incidence increases progressively thereafter.  
 Ethnicity: African Americans have a higher risk to develop prostate 
cancer and the disease occurs at an earlier stage. Furthermore, pros-
tate cancer is associated with a more aggressive clinical course in Af-
rican Americans than in other ethnic groups.  
 Family history: There is a strong inherited component regarding the 
development of prostate cancer; a family history of prostate cancer 
and other cancers can increase the risk. There are genetic factors (es-
pecially germline mutations in DNA repair genes, e.g., BRCA2) 
which seem to play an important role in the development of certain 
types of prostate cancer and may be associated with a more aggres-
sive course of the disease. Genetic risk assessment should be con-
ducted, including a detailed personal and family cancer history in 
first- and second-degree relatives (type of cancer, age at diagnosis 
and ancestry). If a suggestive family history is established, patients 
should be referred for genetic counselling, and genetic testing should 
be conducted.  
 PSA level: The likelihood of the presence of prostate cancer in-
creases with a more elevated PSA value. Although PSA is consist-
ently expressed in almost all prostate cancers, high-grade prostate 
cancer can occur in men with a “normal” PSA level.  
 Free/total PSA ratio (f/t PSA): The percentage of f/t PSA may be 
used for a higher sensitivity of cancer detection in patients with a 
total PSA within the normal range (<4 ng/ml) and to increase the 
specificity to detect prostate cancer when total PSA is in the “grey 
zone” (4.1 to 10 ng/ml).  
 Findings on DRE including prostate nodules, indurations or asym-
metries.  
 Other factors including diet, hormone levels and obesity may have 
some effect on the incidence of prostate cancer; however, the role of 
these factors appears to be limited. 
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A0024: How is prostate cancer currently diagnosed according to published 
guidelines and in practice? 
An elevation in PSA levels or an abnormality on DRE can be a signs of pros-
tate cancer that warrant additional evaluation. There is no consistent PSA 
threshold for defining an abnormal PSA value [9].  
The final diagnosis of prostate cancer is based on the histology of tissue which 
is obtained by conducting a core needle biopsy of the prostate. If the results 
indicate the presence of prostate cancer, a Gleason grade (which correlates 
closely with clinical behaviour) is generated by using architectural features of 
the obtained cells.  
The Gleason grade for the two most prevalent differentiation patterns is used 
to create the Gleason score and is now used in the new grading (grade group) 
system; the latter provides a more accurate risk stratification. Due to the fact 
that the sampling techniques are used for prostate biopsies which have a sub-
stantial potential for missing malignant tissue, the possibility of the presence 
of prostate cancer cannot be ruled out by conducting a biopsy. In case the PSA 
level increases further, or findings on DRE or prostate imaging indicate pros-
tate cancer, a repetition of the biopsy is warranted [9, 19]. 
According to the EAU-ESTRO-ESUR-SIOG
2
 Guidelines on Prostate Cancer 
[20], frequent post-treatment PSA surveillance leads to earlier detection of 
disease progression in nonmetastatic CRPC. Approximately one third of pa-
tients with a rising PSA develop bone metastases within two years. However, 
there is no evidence available demonstrating a benefit for immediate treat-
ment. A consensus statement by the Prostate Cancer Radiographic Assess-
ments for Detection of Advanced Recurrence (RADAR) group suggested the 
conduction of a bone scan and a CT when the PSA level has reached 2 ng/ml. 
If the results are negative, the imaging procedures should be repeated when 
the PSA has reached 5 ng/ml and then again after every doubling of the PSA 
level based on PSA measurement every three months for asymptomatic pa-
tients. If patients are symptomatic, they should undergo relevant investiga-
tion [20]. 
For prostate cancer, differential diagnosis should be considered. Lower uri-
nary tract symptoms including frequency, urgency, nocturia, and hesitancy 
occur commonly among men and are usually related to benign conditions ra-
ther than to prostate cancer. An elevation of the PSA level can be caused by 
transient conditions, such as prostatitis or perineal trauma, and by persistent 
causes such as benign prostate hyperplasia (BPH) [9]. 
 
 
 
                                                             
2
 EAU = European Association of Urology, ESTRO = European Society for Radio-
therapy & Oncology, ESUR = European Society of Urogenital Radiology, SIOG = 
International Society of Geriatric Oncology 
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6 Current treatment 
A0025: How is prostate cancer currently managed according to published 
guidelines and in practice? 
For the treatment of localised prostate cancer, the following approach is rec-
ommended [21]: 
 Localised prostate cancer – low risk: Affected patients have major 
chances to be cured by surgery or radiotherapy, but there is also a 
risk for overtherapy. Therapeutic options include: 
 Active surveillance 
 Radical prostatectomy 
 Percutaneous radiation therapy of the prostate gland (74–
80 Gray) 
 Iodine-125 low dose rate (LDR) brachytherapy (145 Gray) 
 Watchful waiting (palliative approach) 
For all these options, observational studies showed a prostate 
cancer-specific survival rate of 90% to 97% after ten years. 
 Localised prostate cancer – intermediate risk: In this heterogeneous 
group of patients there is a major chance for a cure, although there 
is also a risk for overtherapy. Treatment options include: 
 Percutaneous radiotherapy  
o With 74–80 Gray or 
o In combination with LDR brachytherapy or 
o In combination with endocrine therapy for four to 
six months 
 Active surveillance (application of advanced criteria) 
 Watchful waiting (palliative approach) 
 Localised prostate cancer – high risk: Due to the high risk of disease 
progression, a curative approach is recommended. In case of contra-
indications, a palliative approach (based on symptoms) is recom-
mended. Possible treatment options include: 
 Radical prostatectomy 
 Percutaneous radiation therapy of the prostate gland 
o In combination with endocrine therapy for six 
months or, preferably, 24–36 months or 
o In combination with high dose rate (HDR) brachy-
therapy, possibly with endocrine therapy 
 Watchful waiting (palliative approach). 
According to the National Comprehensive Cancer Center Guidelines [22], for 
patients with CRPC and no signs of distant metastasis, observation can be 
considered if PSADT is >10 months. For patients with a PSADT <10 
months, secondary hormone therapy (apalutamide or enzalutamide may be 
considered) provides an option, because the androgen receptor may remain 
active. Patients with progressive disease despite combined androgen blockade 
can discontinue the antiandrogen to exclude an “antiandrogen withdrawal re-
sponse”. Antiandrogen withdrawal is a potential therapeutic manoeuvre for 
patients with progressive prostate cancer [22, 23]. 
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7 Evidence 
A literature search was conducted on 19 April 2019 in four databases: the 
Cochrane Library, Embase, Ovid Medline and PubMed. Search terms were 
“darolutamide”, “ODM-201”, “castration-resistant prostate cancer”, 
“CRPC”, “prostatic neoplasms, castration-resistant” and “nonmetastatic”. 
The manufacturer was also contacted and submitted eight references (two of 
these had already been identified by systematic literature search). A manual 
search identified 37 additional references (web documents and journal arti-
cles). 
Overall, 95 references were identified. Included in this reported are:  
 Primary and interim analysis data from ARAMIS, a multinational, 
double-blind, placebo-controlled phase III trial to evaluate the effi-
cacy and safety of darolutamide in patients with nonmetastatic 
CRPC [4, 24, 25] and 
 ARADES, an open-label phase 1 dose escalation and randomised 
phase II dose expansion trial, assessing the activity and safety of da-
rolutamide in patients with metastatic CRPC [26]. 
To assess the risk of bias at the study level, the assessment of the methodolog-
ical quality of the evidence was conducted based on the EUnetHTA internal 
validity for randomised controlled trials (RCTs) [27]. Evidence was assessed 
based on the adequate generation of the randomisation sequence, allocation 
concealment, blinding of patient and treating physician, selective outcome re-
porting and other aspects that may increase the risk of bias. Study quality 
details are reported in Table 5 of the Appendix. 
The external validity of the included trials was assessed using the EUnetHTA 
guideline on applicability of evidence in the context of a relative effectiveness 
assessment of pharmaceuticals, considering the following elements: popula-
tion, intervention, comparator, outcomes and setting (see Table 5) [28]. 
To evaluate the magnitude of “meaningful clinical benefit” that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS) was used [29]. In addition, an adapted version (due to perceived lim-
itations) of the ESMO-MCBS was applied [30]. Details of the magnitude of 
the clinically meaningful benefit scale are reported in Table 3. 
 
7.1 Quality assurance  
This report has been reviewed by an internal reviewer and an external re-
viewer. The latter was asked for the assessment of the following quality crite-
ria: 
 How do you rate the overall quality of the report? 
 Are the therapy options in the current treatment section used in clin-
ical practice and are the presented standard therapies correct? 
 Is the data regarding prevalence, incidence and amount of eligible 
patients correct? 
systematic literature 
search in 5 databases:  
63 hits 
 
 
manual search: 37 
additional references 
overall: 95 references 
included: 2 studies 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
applicability of study 
results 
magnitude of 
meaningful clinical 
benefit assessed based 
on ESMO-MCBS 
internal and external 
review  
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 Are the investigated studies correctly analysed and presented (data 
extraction was double-checked by a second scientist)? 
 Was the existing evidence from the present studies correctly inter-
preted? 
 Does the current evidence support the final conclusion? 
 Were all important points mentioned in the report? 
The LBI-HTA considers the external assessment by scientific experts from 
different disciplines a method of quality assurance of scientific work. The fi-
nal version and the policy recommendations are under full responsibility of 
the LBI-HTA. 
 
7.2 Clinical efficacy and safety –  
phase III studies 
The ARAMIS trial [4, 24, 25] is a multinational, randomised, double-blind, 
placebo-controlled, phase III trial evaluating the efficacy and safety of daro-
lutamide compared to placebo in men with nonmetastatic CRPC. Patients 
were enrolled between September 2014 and March 2018; a total of 1,509 pa-
tients underwent randomisation and were assigned in a 2:1 ratio to either the 
darolutamide group (n = 955) or the placebo group (n = 554). Randomisation 
was stratified according to PSA doubling time (≤6 months or ≥6 months) and 
the use of osteoclast-targeted therapy at randomisation (yes/no). Patients 
were eligible to participate in the ARAMIS trial if they had a histologically or 
cytologically confirmed adenocarcinoma of the prostate, CRPC, a baseline 
PSA level of at least 2 ng per millilitre, a PSADT of ten months or less and an 
Eastern Cooperative (ECOG) performance status of 0 or 1. Patients with de-
tectable metastases or a history of metastatic disease were excluded; patients 
with previous seizures or conditions predisposing to a seizure were allowed to 
participate. Detailed inclusion- and exclusion criteria can be found in Table 
5Fehler! Verweisquelle konnte nicht gefunden werden.. 
Patients of both groups had a median age of 74 years; 1,194 patients were 
White, 52 patients were of African descent. The median time from initial di-
agnosis was 86.2 months in patients of the darolutamide group and 84.2 
months in patients of the placebo group. 17% of darolutamide group patients 
and 29% of placebo group patients showed a presence of lymph nodes on cen-
tral imaging review. The median PSADT was 4.4 months (darolutamide 
group) compared to 4.7 months (placebo group); the median serum testos-
terone level was 0.6 nmol/l in patients of either group. The majority of pa-
tients had an ECOG performance status of 0, in particular 68% in the darolu-
tamide group and 71% in the placebo group. A small number of patients, 3% 
in the darolutamide group and 6% in the placebo group, used a bone-sparing 
agent. 19% of patients in either group received one previous hormonal ther-
apy agent, 76% of patients in either group were previously treated with two or 
more hormonal therapy agents. Detailed patient characteristics can be found 
in Table 5Fehler! Verweisquelle konnte nicht gefunden werden.. 
quality assurance 
method 
ARAMIS trial:  
double-blind, placebo-
controlled phase III trial 
patient characteristics: 
 
median age of 74 years 
 
 
median PSADT: 
darolutamide 4.4 
months 
placebo 4.7 months 
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Patients of the darolutamide group received the study drug at a dose of 600 
mg given as two 300 mg tablets twice daily with food, resulting in a total daily 
dose of 1,200 mg. Patients of the placebo group received matching placebo 
tablets. Study treatment was administered until protocol-defined progression, 
discontinuation of the regimen due to adverse events (AEs) or withdrawal of 
consent. Throughout the trial, patients continued to receive ADT. 
Metastasis-free survival (MFS) was the primary endpoint of the ARAMIS 
trial, defined as the time from randomisation to confirmed evidence of distant 
metastasis on imaging or death from any cause, whichever occurred first. Sec-
ondary endpoints were overall survival (OS), the time to pain progression, the 
time to cytotoxic chemotherapy and the time to first symptomatic skeletal 
event. Exploratory endpoints were progression-free survival (PFS) and the 
time to PSA progression, to first prostate cancer-related invasive procedures 
and to initiation of subsequent antineoplastic therapy. 
The data collection cut-off date for the primary analysis was on September 3, 
2018. The median follow-up time was 17.9 months; the median duration of 
treatment was 14.8 months in patients of the darolutamide group and 11.0 
months in patients of the placebo group. 64% (darolutamide group) and 36% 
(placebo group) were still receiving the trial regimen at the time of data cut-
off. 35.5% of patients (darolutamide group) and 63.9% of patients (placebo 
group) discontinued study treatment. 29.5% of darolutamide group patients 
and 36.7% of placebo group patients who discontinued the trial regimen re-
ceived subsequent approved therapy for metastatic CRPC; most frequently 
used subsequent treatments were docetaxel, abiraterone acetate and enzalu-
tamide. Clinical efficacy data are presented in Table 1; AE data are presented 
in Table 2. 
The ARAMIS trial is ongoing until June 2020 (estimated study completion 
date); hence, primary and interim analyses are presented. 
 
7.2.1 Clinical efficacy 
 
D0001: What is the expected beneficial effect of darolutamide on mortality? 
OS was a secondary endpoint of the ARAMIS trial. An interim analysis of OS 
was performed after 136 deaths, showing a lower risk of death in patients re-
ceiving darolutamide than in patients receiving placebo; hazard ratio (HR) 
for death was 0.71, confidence interval (CI) 0.50–0.99, p = 0.045. Median du-
ration of OS has not been reached [24]. 
 
D0006: How does darolutamide affect progression (or recurrence) of nonmet-
astatic CRPC? 
MFS was the primary endpoint of the ARAMIS trial. The primary analysis 
conducted after the occurrence of death or metastasis in 437 patients, showed 
a median MFS of 40.4 months in patients of the darolutamide group versus 
18.4 months in the placebo group (HR for metastasis or death in the darolu-
tamide group was 0.41, 95% CI 0.34–0.50, p < 0.001). The superiority of da-
rolutamide regarding MFS was observed across all pre-specified subgroups 
[24]. 
darolutamide: 600 mg 
twice daily  
(2 x 300 mg tablet), 
total daily dose  
of 1,200 mg 
MFS: primary endpoint 
median follow-up: 
17.9 months,  
median duration of 
treatment: 14.8 months 
(darolutamide group) 
vs. 11.0 months  
(placebo group) 
trial is ongoing, 
primary- and interim 
analysis presented 
lower risk of death with 
darolutamide at the 
time of interim analysis, 
median OS not reached 
MFS prolonged with 
darolutamide:  
40.4 vs. 18.4 months 
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The median time to pain progression, a secondary endpoint of the ARAMIS 
trial, was prolonged in patients of the darolutamide group: 40.3 months as 
compared to 25.4 months in the placebo group (HR 0.65, 95%CI 0.53–0.79, p 
< 0.001). The median time to the first cytotoxic chemotherapy (another sec-
ondary endpoint) was not reported in darolutamide group patients, and was 
38.2 months in placebo group patients (HR 0.43, 95% CI 0.31–0.60, p < 
0.001). The median time to the first symptomatic skeletal event (secondary 
endpoint) was not reported in patients of either group, HR was 0.43, 95% CI 
0.22–0.84, p = 0.01 [24]. 
Median PFS was 36.8 months in patients receiving darolutamide and 14.8 
months in patients receiving placebo (HR for disease progression or death was 
0.38, 95% CI 0.32–0.45, p < 0.001) [24].  
 
D0005: How does darolutamide affect symptoms and findings (severity, fre-
quency) of nonmetastatic CRPC? 
The median time to PSA progression was 33.2 months in the darolutamide 
group and 7.3 months in the placebo group (HR for PSA progression or death 
was 0.13, 95% CI 0.11–0.16, p < 0.001). Regarding the time to first prostate 
cancer-related invasive procedure and the time to initiation of subsequent 
antineoplastic therapy, the median duration of these endpoints was not re-
ported from both treatment groups. HR for the time to first prostate cancer-
related invasive procedure was 0.39, 95% CI 0.25–0.61, p < 0.001. HR for the 
time to initiation of subsequent antineoplastic therapy was 0.33, 95% CI 0.23–
0.47, p < 0.001 [24].  
 
D0011: What is the effect of darolutamide on patients̕ body functions? 
The occurrence of fatigue or asthenic conditions was higher in patients who 
received darolutamide (15.8%) than in patients receiving placebo (11.4%); 
more patients in the darolutamide group (2.9%) than patients in the placebo 
group (0.9%) experienced rash. There was no higher incidence with darolu-
tamide regarding falls, seizures or change in mental status. 
 
D0012: What is the effect of darolutamide on generic health-related quality 
of life? 
D0013: What is the effect of darolutamide on disease-specific quality of life? 
To evaluate the generic health-related (HRQoL) and the disease-specific 
quality of life (QoL) of the ARAMIS trial patients, the following question-
naires were used: the Brief Pain Inventory Short-Form (BPI-SF), the Func-
tional Assessment of Cancer Therapy-Prostate (FACT-P), the prostate cancer-
specific subscale of the FACT-P (FACT-P PCS), the generic EuroQol Group 
5-dimension 3-level (EQ-5D-3L) and the European Organisation for Research 
and Treatment of Cancer quality of life questionnaire urinary symptoms sub-
scale (EORTC-QLQ-PR25). Analyses showed similar results for patient-re-
ported QoL in both groups. Differences in least-squares mean (LSM), time-
adjusted, area-under-the-curve (AUC) scores were statistically significant for 
BPI-SF (pain severity and pain interference scores), FACT-P (Physical Well-
Being, Emotional Well-Being, PCS, General, FACT-P total and Trial Out-
come Index), and the EORTC-QLQ-PR25 urinary symptoms subscale were in 
median time to pain 
progression prolonged 
with darolutamide 
darolutamide: median 
PFS +22 months 
median time to PSA 
progression +25.9 
months 
higher rate of 
fatigue/asthenic 
conditions and rash with 
darolutamide 
QoL assessed by the use 
of BPI-SF, FACT-P, 
FACT-P PCS, EQ-5D-3L, 
EORTC-QLQ-PR25 
 
patient-reported QoL: 
similar in both groups 
 
differences in LSM time-
adjusted AUC scores 
favoured darolutamide, 
but clinically meaningful 
thresholds were not 
reached 
Horizon Scanning in Oncology 
18 LBI-HTA | 2019 
favour of darolutamide. However, the clinically meaningful thresholds were 
not reached [24, 25]. 
 
Table 1: Efficacy results of ARAMIS trial [24, 25] 
Descriptive sta-
tistics and esti-
mate variability 
Treatment group Darolutamide Placebo 
Number of subject 955 554 
Median MFS, months 40.4 18.4 
Median OS, months NR NR 
Median time to pain progression, months 40.3 25.4 
Median PFS, months 36.8 14.8 
Median time to PSA progression, months 33.2 7.3 
BPI-SF pain interference 1.1 1.3 
BPI-SF pain severity 1.3 1.4 
FACT-P (total) 112.9 111.6 
FACT-P PCS 32.4 31.8 
EORTC-QLQ-PR25 (urinary symptoms subscale) 23.7 26.4 
EQ-5D-3L Index Score 0.8 0.8 
EQ-5D-3L VAS 73.3 72.7 
Effect estimate 
per comparison 
 
Comparison groups Darolutamide vs. placebo 
Median MFS HR for metastasis or death 0.41 
95% CI 0.34–0.50 
p-value <0.001 
Median OS HR for death 0.71  
95% CI 0.50–0.99 
p-value 0.045 
Median time to pain progression HR 0.65 
95% CI 0.53–0.79 
p-value <0.001 
 Median PFS HR 0.38 
95% CI 0.32–0.45 
p-value <0.001 
Median time to PSA progression HR 0.13 
95% CI 0.11–0.16 
p-value <0.001 
BPI-SF pain interference Difference -0.2 
MID 2 
BPI-SF pain severity Difference -0.2 
MID 2 
FACT-P (total) Difference 1.3 
MID 10 
FACT-P PCS Difference 0.6 
MID 3 
EORTC-QLQ-PR25 (urinary symptoms subscale) Difference -2.7 
MID 8 
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 EQ-5D-3L Index Score Difference 0.01 
MID - 
EQ-5D-3L Visual Analogue Scale 
 
Difference 0.6 
MID - 
Abbreviations: BPI-SF = Brief Pain Inventory Short-Form, CI = confidence interval, EORTC-QLQ-PR25 =European Organisation for 
Research and Treatment of Cancer Quality of Life, EQ-5D-3L = EuroQol 5-dimensions 3-levels, FACT-P = Functional Assessment of Cancer 
Therapy-Prostate, HR = hazard ratio, MFS = Metastasis-free survival, MID = minimally important difference, NR = not reported, OS = 
overall survival, PCS =prostate cancer subscale, PFS = progression-free survival, PSA = prostate-specific antigen, VAS = visual analogue scale 
 
7.2.2 Safety 
 
C0008: How safe is darolutamide in relation to the comparator(s)? 
AEs of any grade were reported from 83.2% of darolutamide group patients 
and 76.9% of placebo group patients; AEs of grade 3 or 4 were reported in 
24.7% (darolutamide group) and 19.5% (placebo group) of patients. 24.8% of 
darolutamide group patients and 20.0% of placebo group patients experi-
enced serious AEs of any grade. 15.8% and 12.6% of patients had serious AEs 
of grade 3 or 4 in the darolutamide group and placebo group, respectively. 
3.9% of darolutamide group patients and 3.2% of placebo group patients had 
a grade 5 AE; one death in the darolutamide group and two deaths in placebo 
group patients were considered to be related to the study treatment.  
The most common AEs occurring in ≥5% of patients were fatigue (12.1%), 
back pain (8.8%) and arthralgia (8.1%) in darolutamide group patients and 
arthralgia (9.2%), back pain (9.0%) and fatigue (8.7%) in placebo group pa-
tients. The most frequent AEs of special interest (any grade) were fatigue or 
asthenic conditions (15.8%), bone fracture (4.2%) and falls, including acci-
dent (4.2%) in patients of the darolutamide group and fatigue or asthenic con-
ditions (11.4%), falls, including accident (4.7%), and dizziness, including ver-
tigo (4.0%), in placebo group patients.  
Among patients of the darolutamide group, 8.9% of them discontinued treat-
ment due to AEs of any grade and 3.4% of patients stopped the trial regimen 
due to AEs of grade 3 or 4. In the placebo group, AEs of any grade led to dis-
continuation in 8.7% of patients, and 4.3% of patients discontinued receiving 
the study drug due to AEs of grade 3 or 4. 
 
C0002: Are the harms related to dosage or frequency of applying 
darolutamide? 
Massard et al. reported that darolutamide was well tolerated in an open-label 
phase I trial when patients initially received a single 600 mg dose of 
darolutamide (tablet or capsules) and 600 mg twice daily (capsules) in the 
extension phase. All treatment-related AEs were grade 1 and none of the 
patients required dose reductions [4, 31]. Within the scope of the ARADES 
trial, different dosage regimens of darolutamide treatment were assessed. 
Darolutamide was well tolerated up to the highest prespecified dose of 1,800 
mg per day; a maximum tolerated dose was not reached. The most frequently 
reported AEs were of grade 1 or 2 and the AE profile did not differ between 
dose levels [26]. 
AEs grade ≥3: 24.7% in 
darolutamide group vs. 
19.5% in placebo group 
1 death in darolutamide 
group and 2 deaths in 
placebo group 
considered to be related 
to study treatment 
most common AEs in 
the darolutamide group: 
fatigue, back pain, 
arthralgia 
study treatment 
discontinuation due to 
AEs in 8.9% 
(darolutamide group) 
and 8.7%  
(placebo group) 
different dosages up to 
1,800 mg 
darolutamide/day were 
well tolerated in 
previous phase I/II trials 
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According to the ARAMIS trial protocol, patients who are affected by a 
treatment-related grade ≥3 AE that cannot be ameliorated by the use of an 
adequate medical intervention should interrupt the trial regimen until the AE 
improves to grade ≤2. If the treatment interruption lasts longer than 28 days, 
the patient must be withdrawn from the study. If it is considered necessary 
for the safety of a trial participant, the dose of the trial regimen can be reduced 
to 300 mg twice daily. If a patient experiences an AE of grade ≥3 after one 
dose reduction despite medical intervention, withdrawal from study 
treatment is required [4]. 
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of darolutamide? 
On the basis of the known pharmacologic effects of antiandrogens, decreased 
fertility is expected in men who receive darolutamide. In addition, it has to be 
considered that ARAMIS trial participants continue to receive ADT through-
out the trial, which also affects fertility [4]. 
ARAMIS trial: 
interruption of 
treatment  
(≤28 days)/ dose 
reduction allowed 
decreased fertility 
expected 
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Table 2: Most frequent adverse events [24] 
 
Adverse event (according  
to NCI CTCAE version 4.03) 
 
Darolutamide (n = 954) Placebo (n = 554) 
 Any grade  
n (%) 
Grade 3 or 4 
n (%) 
Any grade 
n (%) 
Grade 3 or 4 
n (%) 
Any adverse event 794 (83.2) 236 (24.7) 426 (76.9) 108 (19.5) 
Serious adverse event 237 (24.8) 151 (15.8) 111 (20.0) 70 (12.6) 
Grade 5 adverse event 37 (3.9) - 18 (3.2) - 
Adverse event leading to 
discontinuation of the trial 
regimen 
85 (8.9) 32 (3.4) 48 (8.7) 24 (4.3) 
Adverse events that occurred in ≥5% of patients in either group 
   Fatigue 115 (12.1) 4 (0.4) 48 (8.7) 5 (0.9) 
   Back pain 84 (8.8) 4 (0.4) 50 (9.0) 1 (0.2) 
   Arthralgia 77 (8.1) 3 (0.3) 51 (9.2) 2 (0.4) 
   Diarrhoea 66 (6.9) 0 (0) 31 (5.6) 1 (0.2) 
   Hypertension 63 (6.6) 30 (3.1) 29 (5.2) 12 (2.2) 
   Constipation 60 (6.3) 0 (0) 34 (6.1) 0 (0) 
   Pain in an extremity 55 (5.8) 0 (0) 18 (3.2) 1 (0.2) 
   Anaemia 53 (5.6) 8 (0.8) 25 (4.5) 2 (0.4) 
   Hot flush 50 (5.2) 0 (0) 23 (4.2) 0 (0) 
   Nausea 48 (5.0) 2 (0.2) 32 (5.8) 0 (0) 
   Urinary tract infection 47 (4.9) 6 (0.6) 28 (5.1) 3 (0.5) 
   Urinary retention 33 (3.5) 15 (1.6) 36 (6.5) 11 (2.0) 
Adverse events of interest 
   Fatigue or asthenic conditions 151 (15.8) 6 (0.6) 63 (11.4) 6 (1.1) 
   Bone fracture 40 (4.2) 9 (0.9) 20 (3.6) 5 (0.9) 
   Falls, including accident 40 (4.2) 8 (0.8) 26 (4.7) 4 (0.7) 
   Seizure, any event 2 (0.2) 0 (0) 1 (0.2) 0 (0) 
   Rash 28 (2.9) 1 (0.1) 5 (0.9) 0 (0) 
   Weight decrease, any event 34 (3.6) 0 (0) 12 (2.2) 0 (0) 
   Dizziness, including vertigo 43 (4.5) 2 (0.2) 22 (4.0) 1 (0.2) 
   Cognitive disorder 4 (0.4) 0 (0) 1 (0.2) 0 (0) 
   Memory impairment 5 (0.5) 0 (0) 7 (1.3) 0 (0) 
   Change in mental status 0 (0) 0 (0) 1 (0.2) 0 (0) 
   Hypothyroidism 2 (0.2) 0 (0) 0 (0) 0 (0) 
   Cerebral ischaemia 13 (1.4) 7 (0.7) 8 (1.4) 4 (0.7) 
   Coronary-artery disorder 31 (3.2) 16 (1.7) 14 (2.5) 2 (0.4) 
   Heart failure 18 (1.9) 5 (0.5) 5 (0.9) 0 (0) 
Abbreviations: NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events, n = number 
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7.3 Clinical effectiveness and safety –  
further studies 
The ARADES trial [26], an open-label, multicentre study with a non-random-
ised phase I dose escalation part, a phase II randomised dose expansion part 
and a long-term follow up was conducted to assess darolutamide in patients 
with progressive metastatic CRPC. Eligible patients had histologically con-
firmed adenocarcinoma of the prostate, progressive metastatic disease and a 
PSA higher than 2 ng/ml. Patients with seizure were not excluded; three pa-
tients had a history of seizures.  
In the phase I part of the trial, the 24 enrolled patients received darolutamide 
orally at a starting daily dose of 200 mg, which was increased to 400 mg, 600 
mg, 1,000 mg, 1,400 mg and 1,800 mg. The primary endpoint of the phase I 
part was safety and tolerability. In the phase II part of the study, 110 patients 
received one of three daily doses of darolutamide: 200 mg, 400 mg or 1,400 
mg; the primary endpoint of this study phase was the proportion of patients 
with a PSA response (50% or greater decrease in serum PSA) at week 12. The 
median time of darolutamide administration was 24.8 months in phase I and 
11.0 months in phase II of the ARADES trial. The most common reason for 
discontinuation of the trial regimen was disease progression; 4% of the pa-
tients discontinued due to the occurrence of an AE. Safety analyses showed 
that in the phase I part 93% of the AEs were of grade 1–2. Three patients 
reported eight AEs of grade 3, including fracture, muscle injury, laceration, 
paralytic ileus, pain, presyncope, urinary retention and vomiting; one patient 
had a grade 4 event (lymphoedema). None of the grade 3–4 AEs were deemed 
to be related to the administration of darolutamide. Fourteen of the phase I 
patients entered phase II.  
The phase II analyses showed that 29% of patients in the 200 mg group, 33% 
of patients in the 400 mg group and 33% of patients in the 1,400 mg group 
had a PSA response at 12 weeks. Analyses among the safety population (n = 
124) showed that the most common treatment-emergent AEs were fatigue or 
asthenia in 12% of patients, hot flush in 5% of patients, and decreased appe-
tite in 4% of patients. One patient experienced a treatment-emergent grade 3 
event (fatigue). No treatment-emergent grade 4 AEs occurred and no seizures 
were reported. Limitations of the ARADES trial include the open-label de-
sign, small sample sizes, the lack of control groups and the absence of QoL 
measurement [26].  
 
 
8 Estimated costs 
A0021: What is the reimbursement status of darolutamide? 
Due to the fact that darolutamide is not approved throughout the European 
Union or the US, no cost information is available.  
 
 
ARADES: phase I dose 
escalation and 
randomised phase II 
dose expansion trial 
 
 
 
 
phase I endpoint: 
 safety and tolerability 
 
 
phase II endpoint:  
PSA response rate 
 
 
tolerable safety profile, 
no seizures 
 
 
 
 
 
approx. 1/3 of patients 
had PSA response at 12 
weeks 
 
limitations: open-label, 
small sample sizes, no 
control group, no QoL 
measurement  
no cost information 
available 
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9 Ongoing research 
Currently, the ARAMIS trial (NCT02200614) is the only phase III trial eval-
uating darolutamide in patients with nonmetastatic CRPC. The estimated 
study completion date is 30 June 2020 [32]. 
However, the following two trials are aiming to assess darolutamide in pa-
tients with metastatic prostate cancer:  
 The ARASENS trial (NCT02799602) is a phase III trial assessing 
the efficacy and safety of darolutamide in combination with stand-
ard ADT therapy and docetaxel in patients with metastatic hor-
mone-sensitive prostate cancer. The estimated study completion 
date is August 2022 [33]. 
 ODENZA (NCT03314324) is a prospective, randomised, open-label 
cross-over phase II trial assessing patient preference between daro-
lutamide and enzalutamide by questionnaire in patients with meta-
static CRPC. The estimated study completion date is January 2022 
[32]. 
There are several other phase I and phase II studies assessing darolutamide 
in prostate cancer, and one phase II trial evaluating darolutamide in female 
breast cancer [32, 34]. 
 
 
10 Discussion 
Darolutamide, a novel nonsteroidal androgen receptor, is not currently ap-
proved by the EMA or by the FDA for any indication. Based on data from the 
ARAMIS trial, the manufacturer submitted a marketing authorisation appli-
cation to the EMA for darolutamide for the treatment of patients with non-
metastatic CRPC in March 2019 [5]; in the US, the submission of a New Drug 
Application to the FDA for darolutamide was initiated in December 2018; the 
rolling submission was completed in February 2019 [6]. 
ARAMIS is the only 
ongoing phase III trial 
for the assessed 
indication 
 
 
ARASENS and ODENZA: 
darolutamide in 
metastatic prostate 
cancer 
several ongoing phase 
I/II trials 
darolutamide is 
currently not approved 
by the EMA or the FDA 
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The ARAMIS trial is aiming to investigate the efficacy and safety of darolu-
tamide compared to placebo in men with nonmetastatic CRPC. The trial is 
currently ongoing; thus, presented data are primary and interim results. The 
primary analysis of median MFS showed a gain of 22 months in patients who 
received darolutamide compared to patients who received placebo (HR for 
metastasis or death in the darolutamide group was 0.41). This beneficial treat-
ment effect of darolutamide was observed across all pre-specified subgroups. 
An interim analysis of OS showed a lower risk of death with darolutamide as 
compared to placebo (HR for death was 0.71); however, median OS data have 
not been reached in either group. PFS – an exploratory endpoint - was statis-
tically significantly longer (36.8 months) in patients of the darolutamide 
group than in patients of the placebo group (14.8 months). In patients receiv-
ing darolutamide, the time to pain progression and the time to PSA progres-
sion were prolonged by 14.9 months and 25.9 months, respectively. HRQoL 
and disease-specific QoL were evaluated by the use of five different question-
naires. Even though differences in LSM time-adjusted AUC scores were con-
sistently favouring darolutamide and were statistically significant for BPI-SF, 
FACT-P and the EORTC-QLQ-PR25 urinary symptoms subscale and the 
clinically meaningful thresholds were not reached. Overall, patient-reported 
QoL was similar between the two treatment groups.  
Due to the ongoing status of the ARAMIS trial, no final analysis regarding 
clinically meaningful outcomes, including OS and QoL, is available. How-
ever, to prove the clinical benefit of darolutamide, final analysis and long-
term efficacy data for OS and QoL are required. MFS is a newly established 
surrogate parameter and was recently used as a primary endpoint supporting 
drug approval [35, 36]. Although Xie et al. deemed MFS to be a strong surro-
gate for OS in clinically localised prostate cancer [37], it needs to be demon-
strated whether a benefit in MFS implies a benefit in OS. 
AEs of grade 3 or 4 occurred in 24.7% (darolutamide group) and 19.5% (pla-
cebo group) of patients; most common were hypertension and urinary reten-
tion, occurring in 3.1% and 1.6% in darolutamide group patients and in 2.2% 
and 2.0% of placebo group patients, respectively. 15.8% of darolutamide 
group patients and 12.6% of patients experienced serious AEs. One death in 
the darolutamide group and two deaths in the placebo group were considered 
to be treatment-related. The percentage of patients who discontinued the trial 
regimen due to AEs was similar in either group [24].  
Preclinical studies showed that darolutamide had a tenfold lower blood-brain 
barrier penetration than enzalutamide, suggesting a lower risk of inducing 
Central Nervous System (CNS)–related AEs, as compared to enzalutamide 
[38]. In contrast to other trials evaluating AR antagonists, patients with a his-
tory of seizures or conditions predisposing to seizures were allowed to partic-
ipate in the ARAMIS trial; analysis showed that the incidence of seizures was 
0.2% in both treatment groups and none of the patients with previous seizures 
had a seizure during the trial. ARAMIS trial analysis showed similar inci-
dences of seizure, dizziness, cognitive disorders and memory impairment in 
the two treatment groups, potentially caused by a lower blood-brain barrier 
penetration of darolutamide. However, there is no evidence to confirm this 
potential benefit of darolutamide. Although safety data from the ARADES 
trial [26] has been substantiated by the results of the ARAMIS trial, no mature 
data regarding long-term safety and potential long-term toxicities is available.  
MFS: +22 months  
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To date, ARAMIS is the only phase III trial assessing darolutamide in patients 
with nonmetastatic CRPC; the trial is ongoing until 30 June 2020. Further 
evidence in terms of efficacy and safety of darolutamide may be provided by 
the ARASENS [33] trial and the ODENZA trial [32], even though both trials 
evaluate darolutamide in patients with metastatic CRPC. To fully elucidate 
the role of darolutamide in patients with nonmetastatic CRPC, a direct com-
parison of darolutamide, enzalutamide and apalutamide is required. 
An issue to discuss is the potential advantage of an intervention at the a-symp-
tomatic, nonmetastatic stage of CRPC rather than at a later stage of the dis-
ease. Mateo et al. [39] stated that long-term toxicities of earlier and therefore 
longer drug administration and the associated economic implications have to 
be considered in case of treatment intensification at an early, nonmetastatic 
stage of CRPC. Studies have evaluated the impact of an earlier treatment on 
healthcare costs by considering the drug costs and the benefits of a delay in 
disease progression, AEs that are drug- and disease-related, as well as the eco-
nomic benefit of an improved QoL, are required. To achieve this, the imple-
mentation of prospective trials to directly compare earlier to later interven-
tion is needed [39].  
The ARAMIS trial was conducted as a double-blind study; adequate genera-
tion of randomisation sequence and allocation concealment were described, 
and reasons for discontinuations were reported. Since the trial is currently 
ongoing, final data analysis is lacking. Hence, the reporting bias cannot be 
assessed by now. Other aspects that increase the risk of bias are the funding 
of ARAMIS trial by the manufacturers and their participation in the data 
analysis. Overall, a low risk of bias was detected. In terms of applicability, it 
needs to be noted that patients with African American descent were un-
derrepresented in the ARAMIS trial (52 of 1,509 patients). Since the incidence 
of prostate cancer is higher in African Americans than in other ethnic groups, 
the applicability of results is limited. Final analysis of data of all primary, 
secondary and exploratory endpoints is lacking; hence, the applicability of the 
results in terms of outcomes is limited. Furthermore, the wide range of exclu-
sion criteria, particularly the exclusion of patients with clinically significant 
cardiovascular diseases including uncontrolled hypertension, severe/unstable 
angina pectoris or congestive heart failure New York Heart Association 
(NYHA) Class III or IV, may limit the applicability of the results. 
We applied the ESMO-MCBS in order to assess whether darolutamide satis-
fies the criteria for a “meaningful clinical benefit” (score 4 or 5). Both the 
original v1.1 as well as the adapted version of the MCBS were used. Given the 
non-curative treatment setting of darolutamide, the lack of an evaluation form 
for the study endpoint MFS and the immature OS data, PFS (Form 2b) was 
the basis for the ESMO-MCBS assessment. The application of the scale to the 
ARAMIS study resulted in a grade 3 in both the original and the adapted ver-
sion of the ESMO-MCBS, respectively. Therefore, darolutamide leads to no 
“meaningful clinical benefit” according to the original scale or the adapted 
framework. However, the result of this evaluation has to be taken with cau-
tion, since PFS was not even a secondary study endpoint, but rather an ex-
ploratory one. 
The costs for darolutamide treatment are not yet known. Once the cost infor-
mation on darolutamide is available, a direct comparison of darolutamide, 
enzalutamide and apalutamide treatment will be feasible. At any rate, addi-
tional costs for the continuation of ADT incur. 
ARAMIS is ongoing until 
06/2020 
 
 
direct comparison with 
enzalutamide and 
apalutamide required 
prospective trials 
needed to compare early 
vs. later intervention 
low risk of bias 
 
 
 
 
 
 
 
 
limitations of 
applicability 
ESMO-MCBS: grade 3 
(original & adapted 
scale);  
 
no mature OS data, PFS 
not a secondary 
endpoint → no 
meaningful clinical 
benefit 
no cost information 
available 
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The ARAMIS trial showed that darolutamide provides a prolongation of MFS 
in patients with nonmetastatic CRPC and was associated with better out-
comes regarding disease progression as compared to placebo. However, the 
presented data are the primary and interim analysis; final results of all end-
points are lacking. Hence, the actual clinical benefit of darolutamide is not 
yet proven. In this regard, more data concerning efficacy, safety and long-term 
results is required, as well as a direct comparison with other AR antagonists, 
to determine the optimal treatment for affected patients. Darolutamide is cur-
rently not approved, but may provide an additional treatment option for pa-
tients with nonmetastatic CRPC. 
MFS prolongation, but 
clinical benefit not yet 
proven 
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Table 3: Benefit assessment based on original ESMO-MCBS and adapted benefit assessment based on adapted ESMO-MCBS [29, 30] 
ESMO-
MCBS 
Active  
substance Indication Intention PE Form 
MG standard 
treatment 
Efficacy Safety 
AJ FM 
MG months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Adapt-ed 
ESMO-
MCBS 
Darolutamide 
Nonmet-
astatic 
CRPC 
NC 
MFS
3 
2b >6 months +22 
0.38 
(0.32–0.45) 
HR ≤0.65 AND Gain >3 
months 
3 
+5.2 grade 3–
4 AEs, +0.2 
discontinua-
tion 
ND x 3 
Original 
ESMO-
MCBS 
Darolutamide 
Nonmet-
astatic 
CRPC 
NC 
MFS
3 
2b >6 months  +22 
0.38 
(0.32–0.45) 
HR ≤0.65 AND Gain >3 
months 
3 x ND x 3 
Abbreviations: AJ = Adjustments, CI = confidence interval, CRPC = castration-resistant prostate cancer, ESMO-MCBS = European Society for Medical Oncology-Magnitude of Clinical Benefit Scale, FM = final adjusted magnitude 
of clinical benefit grade, HR = hazard ratio, m = months, MG = median gain, MFS = metastasis-free survival, ND = no difference, PE = primary endpoint, PM = preliminary magnitude of clinical benefit grade, QoL = quality of life 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint of interest, and by score 
adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the exact same score resulting from the use of form 2c. 
To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically favours drugs with a higher degree of uncertainty (broad CI). Hence, we decided 
to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and outcomes that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the 
primary outcome and, therefore, a reason for confounding. Hence, we report the adjustments separately. 
                                                             
3
 PFS was used since there is no form available to evaluate MFS. However, PFS was not even a secondary endpoint, but rather an exploratory one. 
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12 Appendix 
 
Table 4: Administration and dosing of darolutamide [4] 
 Technology Comparator 
Administration mode 
The tablets should be taken with food and a glass 
(about 250 ml) of water, milk or juice (not grape 
juice). The tablets should be swallowed whole. 
Matching placebo twice daily with 
food. 
Description of packaging 
The active ingredient darolutamide will be provided as 
300 mg film-coated tablets for oral administration. 
The tablets are blue oval-shaped tablets embossed 
with a code ‘OR-300’. Each tablet contains approxi-
mately 180 mg lactose 
Placebo film-coated tablets will be pro-
vided as a reference product. The tab-
lets are blue oval-shaped tablets em-
bossed with a code ‘OR-300’. Each tab-
let contains approximately 180 mg lac-
tose. The placebo tablets will be indis-
tinguishable from darolutamide-201 
tablets. 
Total volume contained in 
packaging for sale 
- - 
Dosing 
Darolutamide was administered to ARAMIS trial pa-
tients at a total daily dose of 1200 mg (2 x 300 mg tab-
lets twice daily) 
Placebo tablets were administered to 
patients of the control group in the 
same manner as in patients of the daro-
lutamide group. 
Median treatment duration ARAMIS trial: 14.8 months in the darolutamide group 
ARAMIS trial: 11.0 months in the pla-
cebo group 
Contraindications - - 
Drug interactions 
According to the ARAMIS trial protocol [4], the inter-
action of darolutamide (at therapeutic dose level, 
based on nonclinical data) with other drugs is unlikely. 
Plasma concentration of drugs that are primary me-
tabolised or activated by P450 CYP2C9 or drugs that 
are sensitive substrates to P-glycoprotein (P-gp) inhi-
bition might be affected by darolutamide. Medicinal 
products that are sensitive substrates for P-gp, such as 
digoxin should be used with caution when co-admin-
istered with darolutamide. If patients are treated with 
both darolutamide and drugs metabolised by CYP2C9 
with a narrow therapeutic index, they should be mon-
itored for possible increased therapeutic effects. In pa-
tients who are treated with warfarin, International 
Normalized Ratio (INR) monitoring should be con-
ducted.  
- 
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Table 5: Characteristics of ARAMIS trial 
Title: Darolutamide in nonmetastatic, castration-resistant prostate cancer [4, 24, 25] 
Study identifier NCT02200614, EudraCT Number: 2013-003820-36 
Design Multinational, randomised, double-blind, placebo-controlled, phase III trial 
Duration of main phase: Enrolment: between September 2014 and March 2018 
Data-collection cut-off date for the primary analysis: 3 Sep-
tember 2018 
 Median follow-up time: 17.9 months 
Hypothesis Superiority 
Funding Bayer HealthCare and Orion Pharma 
Treatment groups 
 
Intervention (n = 955) 
Patients received darolutamide 600 mg given as two 300 
mg tablets twice daily (a daily dose of 1200 mg) with food 
until protocol-defined progression, discontinuation of the 
regimen because of AEs, or withdrawal of consent. Patients 
continued to receive ADT (luteinising hormone-releasing 
hormone agonist or antagonist) throughout the trial. 
Placebo (n = 554) 
Patients received matching placebo for darolutamide (2 
tablets) orally with food. Patients continued to receive ADT 
(luteinising hormone-releasing hormone agonist or antag-
onist) throughout the trial. 
Endpoints and definitions 
 
Metastasis-free survival 
(primary endpoint) 
 
MFS 
Defined as the time from randomisation to confirmed evi-
dence of distant metastasis on imaging or death from any 
cause, whichever occurred first. 
Overall survival (sec-
ondary endpoint) OS 
Defined as time from randomisation to date of death from 
any cause. 
Time to pain progres-
sion (secondary end-
point) 
- 
Defined as either an increase of ≥2 points from baseline in 
the score assessed with the BPI-SF questionnaire or initia-
tion of opioid treatment for cancer pain, whichever oc-
curred first. 
Time to first sympto-
matic skeletal event 
(secondary endpoint) 
SSE 
Defined as external-beam radiation therapy to relieve skel-
etal symptoms, new symptomatic pathologic bone fracture, 
occurrence of spinal cord compression, or tumour-related 
orthopaedic surgical intervention. 
Time to first cytotoxic 
chemotherapy (second-
ary endpoint) 
- Defined as time from randomisation to initiation of the first cytotoxic chemotherapy. 
Progression-free sur-
vival (exploratory end-
point) 
PFS 
Defined as the time from randomisation to evidence of 
any radiographic disease progression, including local re-
lapse or new pathologic lymph nodes, or death from any 
cause, whichever occurred first.  
Time to first prostate 
cancer-related invasive 
procedure (exploratory 
endpoint) 
- 
Defined as time from randomisation to date of first pros-
tate cancer-related invasive procedure. Prostate cancer-re-
lated invasive procedure is defined as any procedure needed 
for alleviation of symptoms, signs or findings caused by pro-
gression of prostate cancer (e.g., catheterisation of the 
bladder, percutaneous drainage of hydronephrosis, pallia-
tive electroresection of the prostate, etc.). 
Time to initiation of 
subsequent antineo-
plastic therapy (explor-
atory endpoint) 
- Defined as time from randomisation to initiation of first 
antineoplastic therapy. 
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Title: Darolutamide in nonmetastatic, castration-resistant prostate cancer [4, 24, 25] 
Study identifier NCT02200614, EudraCT Number: 2013-003820-36 
Time to PSA progres-
sion (exploratory end-
point) 
- 
PSA progression is defined according to the Consensus 
Guidelines of the PCWG2. 
 For patients with declines from baseline at week 16, 
the PSA progression is defined as the date that a ≥25% 
PSA increase and an absolute increase of ≥2 ng/ml 
above the nadir is documented, which is confirmed by 
a second consecutive value obtained 3 or more weeks 
later. 
 For patients with no decline from baseline at week 16, 
the PSA progression is defined as the date that a ≥25% 
PSA increase in PSA along with an absolute increase of 
≥2 ng/ml above the baseline is documented, which is 
confirmed by a second consecutive value obtained 3 or 
more weeks later. 
Early increases in PSA values before the 16 weeks are not 
considered as PSA progression. 
PSA response (explora-
tory endpoint) - 
Defined as a decline of at least 50% from baseline in the 
PSA level, according to PCWG2 criteria. 
Deterioration in ECOG 
performance status(ex-
ploratory endpoint)  
- Defined as an increase to a score of 3 or higher. 
Quality of life  QoL - 
Database lock 
Entire database will be locked after all data for the follow-up period of the study have been en-
tered and queries resolved.  
Results and analysis  
Analysis description Primary analysis 
The sample size was calculated on the basis of the primary end point, metastasis-free survival. As-
suming a HR of 0.71 for death or metastasis in the darolutamide group, we calculated that a sample 
of 1,500 patients (randomly assigned in a 2:1 ratio to receive darolutamide or placebo) with approxi-
mately 385 primary end-point events would provide the trial with 91% power to detect a significant 
difference in MFS with the use of a log-rank test at a two-sided significance level of 0.05.The full ITT 
population, which was made up of all patients who underwent randomisation, was included in the 
analysis of the primary end point; patients with metastases at baseline were counted as having an 
event at randomisation. Subgroup analyses of MFS and OS were performed to determine the effect 
of demographic or baseline characteristics. Randomisation stratification factors were used to adjust 
analyses of the primary and all secondary efficacy end points. Data from patients without events 
were censored at the last assessment date. Kaplan–Meier curves, including median survival times and 
their 95% CIs, were calculated; the HR was calculated with a Cox proportional-hazards model. Sec-
ondary and exploratory end points were analysed with the same methods as the primary end point, 
with the exception of the percentage of patients with PSA response and percentage of patients with 
deterioration in ECOG performance status, which were analysed with the Cochran–Mantel–Haenszel 
test. Secondary end points were evaluated in a hierarchical order, with a significance level of 0.05 
split between the primary analysis and final analysis (planned to occur after 240 deaths from any 
cause) of secondary endpoints. The end point of OS was used to determine the alpha spend and sig-
nificance threshold for each of the secondary end points. For QoL variables, an analysis of covariance 
model was used to compare the time-adjusted AUC between groups, with covariates for baseline 
scores and randomisation stratification factors. The least-squares mean and 95% confidence interval 
was estimated for each group and for the difference between the groups. Statistical analysis and 
generation of patient data listings were performed with the use of SAS for Windows, version 9.2 (SAS 
Institute). Incomplete data on event occurrence dates were imputed as the earliest possible date. 
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Title: Darolutamide in nonmetastatic, castration-resistant prostate cancer [4, 24, 25] 
Study identifier NCT02200614, EudraCT Number: 2013-003820-36 
Analysis population  
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion 
 Males aged ≥18 years 
 Histologically or cytologically confirmed adenocarcinoma of the prostate 
without neuroendocrine differentiation or small cell features 
 CRPC defined as 3 rising PSA levels after the nadir taken at least 1 week 
apart during ADT. If the patient has a history of antiandrogen use, the 
most recent PSA value must be obtained at least 4 weeks after anti-an-
drogen withdrawal. 
 Castrate level of serum testosterone <1.7 nmol/l (50 ng/dl) on GnRH ago-
nist or antagonist therapy or after bilateral orchiectomy at screening or 
Day 1 visit. Patients who have not undergone bilateral orchiectomy must 
continue GnRH therapy during the study. 
 PSADT of ≤10 months and PSA ≥2 ng/ml at screening. 
 ECOG performance status of 0-1. 
 Blood counts at screening: haemoglobin ≥ 9.0 g/dl, absolute neutrophil 
count ≥ 1500/μ l (1.5×109/l), platelet count ≥ 100,000/μ l (100×109/l) (pa-
tient must not have received any growth factor or blood transfusion 
within 7 days of the haematology laboratory obtained at screening). 
 Screening values of serum ALT and AST ≤ 2.5 x ULN, total bilirubin ≤ 1.5 x 
ULN (except patients with a diagnosis of Gilbert’s disease), creatinine 
≤ 2.0 x ULN.  
 Sexually active patients, unless surgically sterile, must agree to use con-
doms as an effective barrier method and refrain from sperm donation 
during the study treatment and for 3 months after the end of the study 
treatment. 
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Title: Darolutamide in nonmetastatic, castration-resistant prostate cancer [4, 24, 25] 
Study identifier NCT02200614, EudraCT Number: 2013-003820-36 
Analysis population 
(continuation) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exclusion 
 History of radiographically documented metastatic disease at any time or 
presence of detectable metastases by blinded central reading within 42 days 
prior to start of study treatment. Presence of pelvic lymph nodes <2 cm in 
short axis below the aortic bifurcation is allowed. 
 Symptomatic local-regional disease that requires medical intervention includ-
ing moderate/severe urinary obstruction or hydronephrosis due to prostate 
cancer. 
 Acute toxicities of prior treatments and procedures not resolved to grade ≤ 1 
or baseline before randomisation. 
 Prior treatment with:  
 second-generation AR antagonists such as enzalutamide and apalutam-
ide, or darolutamide or other investigational AR antagonists 
 CYP17 enzyme inhibitors, such as abiraterone acetate, TAK-700; or 
 oral ketoconazole for longer than 28 days. 
 Use of oestrogens or 5-α  reductase inhibitors (finasteride, dutasteride) within 
28 days before randomisation and AR antagonists (bicalutamide, flutamide, 
nilutamide, cyproterone acetate) at least 28 days before screening. 
 Prior chemotherapy or immunotherapy for prostate cancer, except adju-
vant/neoadjuvant treatment completed >2 years before randomisation. 
 Use of systemic corticosteroid with dose greater than the equivalent 10 mg of 
prednisone/day within 28 days before randomisation. 
 Radiation therapy (EBRT), brachytherapy, or radiopharmaceuticals) within 12 
weeks before randomisation. 
 Severe or uncontrolled concurrent disease, infection or comorbidity that, in 
the opinion of the investigator, would make the patient inappropriate for en-
rolment. 
 Treatment with an osteoclast-targeted therapy (bisphosphonate or deno-
sumab) to prevent skeletal-related events within 12 weeks before randomisa-
tion. Patients receiving osteoclast-targeted therapy to prevent bone loss at a 
dose and schedule indicated for osteoporosis may continue treatment at the 
same dose and schedule. 
 Known hypersensitivity to the study treatment or any of its ingredients. 
 Major surgery within 28 days before randomisation. 
 Any of the following within 6 months before randomisation: stroke, myocar-
dial infarction, severe/unstable angina pectoris, coronary/peripheral artery by-
pass graft; congestive heart failure NYHA Class III or IV. 
 Uncontrolled hypertension as indicated by a systolic blood pressure ≥ 160 
mmHg or diastolic blood pressure ≥ 100 mmHg at screening. 
 Prior malignancy. Adequately treated basal cell or squamous cell carcinoma of 
skin or superficial bladder cancer that has not spread behind the connective 
tissue layer (i.e., pTis, pTa, and pT1) is allowed, as well as any other cancer for 
which treatment has been completed ≤ 5 years ago and from which the pa-
tient has been disease-free. 
 Gastrointestinal disorder or procedure that expects to interfere significantly 
with absorption of study treatment. 
 Active viral hepatitis, active HIV, or chronic liver disease. 
 Treatment with any investigational drug within 28 days before randomisa-
tion. 
 Any condition that, in the opinion of the investigator, would impair the pa-
tient’s ability to comply with the study procedures. 
 Unable to swallow study medications and comply with study requirements. 
 
Characteristics 
 
  
Intervention 
n = 955 
 
Control 
n = 554 
 Median age (range),  
years 
74 (48-95) 74 (50-92) 
Geographic region, n  
(%) 
   North America 
   Asia-Pacific 
   Rest of the World 
 
 
108 (11) 
119 (12) 
728 (76) 
 
 
76 (14) 
67 (12) 
411 (74) 
Median time from ini-
tial 
diagnosis (range),  
months 
 
 
 
86.2 (2.6-337.5) 
 
 
 
84.2 (0.5-344.7) 
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Title: Darolutamide in nonmetastatic, castration-resistant prostate cancer [4, 24, 25] 
Study identifier NCT02200614, EudraCT Number: 2013-003820-36 
Analysis population 
(continuation) 
Presence of lymph 
nodes on central imag-
ing review, n (%) 
   Yes 
   No 
 
 
 
163 (17) 
792 (83) 
 
 
 
158 (29) 
396 (71) 
Medium serum PSA  
level (range), ng/ml 
 
9.0 (0.3-858.3) 
 
9.7 (1.5-885.2) 
PSA doubling time  
   Median (range),  
   months 
    ≤6 months, n (%) 
    ≥6 months, n (%) 
 
 
4.4 (0.7-11.0) 
667 (70) 
288 (30) 
 
 
4.7 (0.7-13.2) 
371 (67) 
183 (33) 
Median serum testos-
terone level (range), 
nmol/litre 
 
 
0.6 (0.2-25.9) 
 
 
0.6 (0.2-7.3) 
ECOG performance sta-
tus, n (%) 
   0 
   1 
 
 
650 (68) 
305 (32) 
 
 
391 (71) 
163 (29) 
Use of bone-sparing 
agent, n (%) 
   Yes 
   No 
 
 
31 (3) 
924 (97) 
 
 
32 (6) 
522 (94) 
Previous hormonal 
therapy agents re-
ceived, n (%) 
   One 
   Two or more 
   Not applicable 
 
 
 
177 (19) 
727 (76) 
51 (5) 
 
 
 
103 (19) 
420 (76) 
31 (6) 
Applicability of evidence 
Population 
Patients of African American descent were underrepresented in the ARAMIS trial (52/1509 patients). 
Since the incidence of prostate cancer is higher in African Americans than in other ethnic groups, the 
applicability of results is limited. 
Intervention 
Darolutamide is not approved; hence there are no approved licenses or other treatment recommen-
dations available. 
Comparators 
In the ARAMIS trial, a placebo was selected as a comparator. A direct comparison to the androgen-
receptor inhibitors apalutamide and enzalutamide would be of interest. 
Outcomes 
There is evidence that MFS was significantly longer with darolutamide compared to placebo in men 
with nonmetastatic CRPC. However, the reported data are primary and interim analysis data; since 
the ARAMIS trial is ongoing, final analysis data are lacking. 
Setting 
The ARAMIS trial was conducted in 36 countries worldwide at 409 centres. No issue of setting ap-
plicability was identified. 
Abbreviations: ADT = androgen-deprivation therapy, AE = adverse event, ALT = alanine transaminase, AR = androgen receptor, AST = Aspartate 
transaminase, AUC = area under the curve, BPI-SF = Brief Pain Inventory Short-Form, CI = confidence interval, CRPC = castration-resistant, 
prostate cancer, ECOG = Eastern Cooperative Oncology Group, GnRH = gonadotropin releasing hormone, HIV = human immunodeficiency virus, 
HR = hazard ratio, ITT = intention-to-treat, MFS = metastasis-free survival, NYHA = New York Heart Association PCWG2 = Prostate Cancer 
Clinical Trials Working Group 2, PFS = progression-free survival, PSA = prostate-specific antigen, PSADT = PSA doubling time, QoL = Quality 
of life, SEE = symptomatic skeletal event, ULN = upper limit normal 
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Table 6: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled trials) [4, 24, 27] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: Randomisation will be performed centrally 
blocking by centre according to the design of the study using a 2-step procedure. Firstly, a sepa-
rate master randomisation schedule and study treatment package list will be created using ran-
domly permuted blocks. Secondly, randomly permuted blocks from the master randomisation 
schedule are assigned to the study centres. 
yes 
Adequate allocation concealment: An IRT (also called IVRS) system assigns patients to receive 
either darolutamide or matching placebo using allocation ratio 2:1, respectively. 
yes 
Blinding: 
Patient Yes 
Treating physician yes 
Selective outcome reporting unlikely: Since the ARAMIS trial is ongoing, only data from the pri-
mary analysis and the interim analysis are available; final analysis data are lacking. No median 
OS data was reported. Reasons for discontinuations have been reported. 
Unclear 
No other aspects which increase the risk of bias: The trial was funded by Bayer HealthCare and 
Orion Pharma. The data were collected by the investigators, analysed by statisticians who were 
employed by the sponsors, and interpreted by the authors, including employees of the sponsors. 
Bayer HealthCare provided funding for medical writing and editing assistance. 
No 
Risk of bias – study level low 
Abbreviations: IRT = interactive response technology, IVRS = interactive voice response system 
